Tofacitinib citrate - CAGE Bio
Alternative Names: 1% Tofacitinib - CAGE Bio; CGB-500; Tofacitinib citrate ointmentLatest Information Update: 22 Apr 2025
At a glance
- Originator CAGE Bio
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Atopic dermatitis
Most Recent Events
- 11 Apr 2025 CAGE Bio plans a phase II trial for Atopic dermatitis (In adolescents, In adults, In the elderly) in unknown location (Topical, Ointment) (NCT06923228)
- 09 Oct 2023 CAGE Bio plans to initiate registrational trials for Atopic dermatitis (Unspecified, Liquid)
- 09 Oct 2023 CAGE Bio plans to initiate dose ranging trial for Atopic dermatitis (Unspecified, Liquid)